Successful Treatment of Molecular Relapse in NPM1-positive AML Using 5-Azacytidine

Leukemia - United Kingdom
doi 10.1038/leu.2009.204
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Evaluating the Potential of Using 5-Azacytidine as an Epimutagen

Canadian Journal of Botany
1999English

Teriflunomide Restores 5-Azacytidine Sensitivity via Activation of Pyrimidine Salvage in 5-Azacytidine-Resistant Leukemia Cells

Oncotarget
Oncology
2017English

NPM1 Mutant Variant Allele Frequency Correlates With Leukemia Burden but Does Not Provide Prognostic Information in NPM1-mutated AML

American Journal of Hematology
Hematology
2019English

Molecular Genetics of AML

Best Practice and Research in Clinical Haematology
OncologyClinical Biochemistry
2012English

The Combination of NPM1, DNMT3A and IDH1/2 Mutations Leads to Inferior Overall Survival in AML

American Journal of Hematology
Hematology
2019English

Modern Strategies in AML Treatment

Russian Journal of Children Hematology and Oncology
2016English

The Prognostic Significance of Chromosome 17 Abnormalities in Patients With Myelodysplastic Syndrome Treated With 5‐azacytidine: Results From the Hellenic 5‐azacytidine Registry

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

AML Patients Relapse Post-Transplantation by Escaping Transferred Immune Cells

Cancer Discovery
Oncology
2019English

Molecular Targeting and Treatment of EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibody L8A4

Clinical Cancer Research
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy